Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma

Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma

Background Metastatic cholangiocarcinoma (CC), a form of gastrointestinal cancer that originates from the bile ducts, cannot be cured by currently available therapies, and is associated with dismal prognosis. In a previous case report, adoptive transfer of autologous tumor infiltrating lymphocytes (...

Full description

Bibliographic Details
Main Authors:	Yong Li, Steven A Rosenberg, Paul Robbins, Billel Gasmi, Todd D Prickett, Jared J Gartner, Devikala Gurusamy, Vid Leko, Victoria Hill, Bradley Sinclair White, Sivasish Sindiri, Shirley Nah
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/11/4/e006303.full

Similar Items

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
by: Tianyu Wu MD, et al.
Published: (2021-02-01)

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
by: Jing Wang, et al.
Published: (2020-07-01)

FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
by: Anna Saborowski, et al.
Published: (2020-09-01)

The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
by: Dong Liu, et al.
Published: (2022-04-01)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
by: Qianmeng Lin, et al.
Published: (2022-08-01)

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
by: Giovanni Brandi, et al.
Published: (2024-02-01)

FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma
by: Chunye Huang, et al.
Published: (2022-01-01)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
by: Xiaohong Pu, et al.
Published: (2023-11-01)

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
by: Michael Bitzer, et al.
Published: (2021-09-01)

Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
by: Sarinya Kongpetch, et al.
Published: (2020-11-01)

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
by: Xiaohong Pu, et al.
Published: (2021-03-01)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
by: Lei Zhang, et al.
Published: (2023-06-01)

Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes
by: Chaoqun Li, et al.
Published: (2023-12-01)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
by: Daniel Walden, et al.
Published: (2022-08-01)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
by: Salati M, et al.
Published: (2021-10-01)

Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand
by: Piyapharom Intarawichian, et al.
Published: (2022-12-01)

Large Intrahepatic Cholangiocarcinoma with Tumor Infiltrative Lymphocytes and Autoimmune Hepatitis-Like Features
by: Sadanobu Izumi, et al.
Published: (2010-02-01)

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
by: Michael E. Lidsky, et al.
Published: (2022-10-01)

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
by: Patrick C. Lee, et al.
Published: (2021-04-01)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
by: Giovanni Brandi, et al.
Published: (2023-04-01)

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma
by: Stephan Spahn, et al.
Published: (2024-02-01)

The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression
by: Nianli Liu, et al.
Published: (2023-10-01)

Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy
by: Alexander Scheiter, et al.
Published: (2021-03-01)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
by: Shun Ishido, et al.
Published: (2023-07-01)

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
by: Pashtoon Murtaza Kasi
Published: (2020-08-01)

Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer
by: Chengcheng Yang, et al.
Published: (2022-09-01)

A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma
by: Zhenzhen Chu, et al.
Published: (2023-12-01)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
by: Olaf Neumann, et al.
Published: (2023-03-01)

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
by: Mitesh J Borad, et al.
Published: (2014-02-01)

Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle
by: Bo Qiu, et al.
Published: (2019-12-01)

1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
by: Steven A Rosenberg, et al.
Published: (2023-11-01)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
by: Caroline Ea, et al.
Published: (2022-06-01)

Differential regulation of FGFR3 controls FGFR1:FGFR3 balance in chondrocytes after cartilage injury
by: Khan, S, et al.
Published: (2016)

Prognostic Significance of NLR, PLR, LMR and Tumor Infiltrating T Lymphocytes in Patients Undergoing Surgical Resection for Hilar Cholangiocarcinoma
by: Zhi-qiang Lin, et al.
Published: (2022-06-01)

Imaged periductal infiltration: Diagnostic and prognostic role in intrahepatic mass-forming cholangiocarcinoma
by: Kenichiro Okumura, et al.
Published: (2024-06-01)

Isolated Liver Hilar Infiltration by IgG4 Inflammation Mimicking Cholangiocarcinoma
by: Laurent Bochatay, et al.
Published: (2016-10-01)

FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
by: Paulina Chmiel, et al.
Published: (2022-12-01)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
by: Guo‐Ming Shi, et al.
Published: (2023-02-01)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
by: Andrew J. Weickhardt, et al.
Published: (2022-05-01)